

**UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK**

GE HEALTHCARE BIO-SCIENCES AB, GE
HEALTHCARE BIO-SCIENCES
CORPORATION, and GENERAL ELECTRIC
COMPANY,

Plaintiffs,

v.

BIO-RAD LABORATORIES, INC.,

Defendant.

Civil Action No. 14-CV-7080 (LTS)

Hon. Laura Taylor Swain

ORAL ARGUMENT REQUESTED

**PLAINTIFFS' AMENDED NOTICE OF MOTION AND MOTION
FOR PRELIMINARY INJUNCTION**

Pursuant to Federal Rule of Civil Procedure 65 and 35 U.S.C. § 283, Plaintiffs GE Healthcare Bio-Sciences AB (“Bio-Sciences AB”), GE Healthcare Bio-Sciences Corporation (“Bio-Sciences Corp.”) and General Electric Company (“General Electric Co.”) (collectively, “GE” or “Plaintiffs”), hereby move this Court for a preliminary injunction against Bio-Rad Laboratories, Inc. (“Bio-Rad”), enjoining Bio-Rad from making, using, selling, offering for sale, or importing into the United States its Next Generation Chromatography (“NGC”) system or any other imitation thereof that likely infringes U.S. Patent No. 8,821,718 (the ““718 patent”), entitled “Automated Fluid Handling System,” which was duly issued by the U.S. Patent and Trademark Office on September 2, 2014 to Johan Blomberg and Mats Lundkvist and assigned to Bio-Sciences AB.

GE is likely to succeed on the merits of the claims it asserted in its complaint, and will be irreparably harmed without an Order enjoining Bio-Rad. Further, the balance of hardship weighs in favor of GE, and it is in the public interest to enjoin Bio-Rad, as requested.

In support of this Motion, GE submits herewith the accompanying Memorandum of Points and Authorities, the supporting declarations of Jennifer Sklenar, Nigel Darby, and Carl Scandella, Ph.D., and all other pleadings, relevant evidence of record, and argument as the Court shall permit.

Pursuant to Rule A(2)(b)(ii) of the Court's Individual Practices Rules, and as more fully detailed in the Declaration of Jennifer Sklenar in Support of Plaintiffs' Motion for Preliminary Injunction ("Sklenar Decl."), counsel for GE certifies that, on September 2, 2014, counsel for GE sent a letter via certified mail to John J. Cassingham, patent counsel for Bio-Rad, advising Bio-Rad: (i) that the '718 patent had issued; (ii) that GE had filed suit against Bio-Rad in this Court on September 2; and (iii) that the basis of GE's allegations was that Bio-Rad infringed the '718 patent by making, using, providing, offering to sell, and/or selling its NGC system. *See* Sklenar Decl. ¶ 16 & Ex. O. Counsel for GE requested that Bio-Rad immediately cease all manufacture, marketing and sales of the NGC system and agree to refrain from making, marketing, or selling the NGC system for the term of the '718 patent. *Id.* Counsel for GE requested a response by the close of business on September 8, 2014. *Id.* As of the filing of this Amended Notice of Motion and Motion, counsel for GE had not received a response from Bio-Rad to its September 2 correspondence. *Id.* ¶ 16.

For these reasons, as well as those set forth more fully in the accompanying memorandum of law, GE asks that its Motion for a Preliminary Injunction be granted.

Dated: September 10, 2014

Respectfully submitted,

/s/ Matthew T. Salzmann

Matthew T. Salzmann
ARNOLD & PORTER LLP
399 Park Avenue
New York, NY 10022-4690
Telephone: +1 212 715 1000
Facsimile: +1 212 715 1399
matthew.salzmann@aporter.com

Of counsel:

Matthew Wolf
ARNOLD & PORTER LLP
555 Twelfth Street, N.W.
Washington, DC 20004
Telephone: +1 202 942 5000
Facsimile: +1 202 942 599
Matthew.Wolf@aporter.com

Jennifer Sklenar
Ryan M. Nishimoto
Kristen L. Johns
ARNOLD & PORTER LLP
777 South Figueroa Street, 44th Floor
Los Angeles, California 90017-5844
Telephone: + 1 213.243.4000
Facsimile: +1 213.243.4199
Jennifer.Sklenar@aporter.com
Ryan.Nishimoto@aporter.com
Kristen.Johns@aporter.com

Attorneys for Plaintiffs
GE Healthcare Bio-Sciences AB
GE Healthcare Bio-Sciences Corporation
General Electric Company